A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Celgene
Study ID
NCT06163898
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Alnuctamab — DRUG
    Specified dose on specified days
  • Mezigdomide — DRUG
    Specified dose on specified days
  • Dexamethasone — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

Key Dates

Start date
Feb 27, 2024
Status verified
Apr 2026
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025

Study Design

Enrollment
4 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A
  • Experimental: Arm B1
  • Experimental: Arm B2
  • Experimental: Arm C1
  • Experimental: Arm C2

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up until 28 days after the last participant discontinues mezigdomide or 80 days after the last participant discontinues alnuctamab, whichever is longer (up to approximately 5 years) ]

Locations (3)

FacilityCityStateZIPSite coordinators
Local Institution - 0033BirminghamAlabama35294-
Local Institution - 0035New HavenConnecticut06511-
Local Institution - 0018New YorkNew York10065-

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Local Institution - 0033· Birmingham, ALLocal Institution - 0035· New Haven, CTLocal Institution - 0018· New York, NY

Related Studies